By Wayne Koberstein, Executive Editor
Proteon Therapeutics has the singular purpose of treating the bane of nearly all kidney dialysis patients — stenosis and failure of the surgically placed vascular access for hemodialysis. Access failure leads to thrombosis and surgical interventions to restore blood flow such as thrombectomy, angioplasty, and often creation of a new access. Proteon's PRT-201, a "locally-acting recombinant human elastase," is applied to the external surface of the artery and vein during the surgical procedure. Having completed a Phase 2 trial and with FDA orphan and fast-track status, the drug is intended to reduce tissue growth inside vessels that causes poor blood flow, thrombosis, and vascular access failure.
By Tracy Worzella, Promega Corporation; and Brad Larson, Applications Department, BioTek Instruments, Inc.
Pharmaceutical companies are increasingly exploring new biologic and biosimilar products, and thus increasing monoclonal antibody (mAb) immunotherapeutic research.
By K. Christopher Min, Yan Jin, and Vikram Gossain
We have been studying rhodopsin with an interest in determining the conformational change that leads to signal transduction in this class of receptors.
By A. Lennaertz, S. Knowles, J.C. Drugmand, and J. Castillo, ATMI LifeSciences
Wild-type or recombinant viruses used as vaccines and human gene therapy vectors are an important developmental tool in modern medicine. Some have demonstrated high potential such as lentivirus, paramyxovirus, and adeno-associated-virus (AAV).
By Dr. Kirk Beebe
Cancer is an extraordinarily complex disease involving a heterogeneous mix of genetically mercurial cancer cells, stroma, and microenvironment across at least 200 different cancer types. Even with a specific cancer type, heterogeneity within patients impairs clinical development. Thus, the clinical challenges are substantial — to produce a meaningful regression or survival benefit based on targeting an important aspect or aspects of this complex biology.